Oxford University Innovation Limited

Sterling IP Limited

Nascient Limited

Princeton University

Isis Innovation Limited

Imperial Innovations Limited

Kim Suzanne Midwood

Patrick John Hextall

Philip Bland-Ward

Nigel Burns

Susan Rebecca Aungier

Jagdeep Nanchahal

Jeffrey J Schwartz

Michael J Avaltroni

Ellen S Gawalt

Jean E Schwarzbauer

Patrick John Venables

Eric Culbert

Brian Maurice Foxwell

Brian Maurice John Foxwell

There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.

Anti-tenascin C antibodies and uses thereof

The present disclosure relates to antibodies and binding fragments to a Tenascin, in particular the FBG domain of a Tenascin, which are potentially less immunogenic than the parent antibody. The disclosure also relates to compositions comprising the antibody or binding fragment and use of any one of the same for diagnosis, prognosis and/or treatment of disorders such as those associated with chronic inflammation. The disclosure further provides methods of making the antibodies.

Human antibodies and binding fragments thereof to tenascin

Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-&#x3b1; antagonist. TNF-&#x3b1; antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.

Treatment for Dupuytren's disease

Treatment for dupuytren's disease

The invention relates to a method of determining the inflammatory disorder status of a subject comprising detecting the presence or absence, or the level, of (i) citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C; and/or (ii) autoantibodies with specificity for citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C, in a sample from said subject.

Biomarker and uses thereof

Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-&#x3b1; antagonist. TNF-&#x3b1; antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such ascollagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.

The present invention provides a dense-coverage, adherent phosphorous-based coating on the native oxide surface of a material. Disclosed phosphorous-based coatings include phosphate and organo-phosphonate coatings. The present invention also provides further derivatization of the phosphorous-based coatings to yield dense surface coverage of chemically reactive coatings and osteoblast adhesion-promoting and proliferation-promoting coatings on the native oxide surface of a titanium material.

Enhanced bonding layers on titanium materials

Growing community of inventors

London, United Kingdom

Kim Suzanne Midwood